Pentagamavunone-1は,ミトス停止によって媒介される過剰なMYCN/NCYM発現を標的とし,肝細胞がんの増殖を抑制する
Dhania Novitasari1,2,3, Ikuko Nakamae1, Noriko Yoneda-Kato1
1Laboratory of Tumor Cell Biology, Institute for Research Initiatives, Nara Institute of Science and Technology, Nara, Japan.
Cancer gene therapy
|September 1, 2025
まとめ
ペントガマヴノン-1 (PGV-1) は,細胞循環停止と衰老を誘導することによって,肝細胞癌 (HCC) 細胞の成長を効果的に抑制する. このカルキュミンの類型は,MYCN過剰発現の肝がんの標的治療として有望である.
科学分野:
- 肝細胞がん (HCC) 研究
- 癌の生物学
- 薬物の発見
背景:
- 肝臓細胞癌 (HCC) は,進行した段階で頻繁に診断される肝臓癌です.
- ソラフェニブのような現在の治療法は 一部の患者では有効性が限られており 新しい治療法の必要性を高めています
- MYCN/NCYM腫瘍遺伝子の過剰発現は,HCCの発症に関与している.
研究 の 目的:
- HCC細胞に対するカルキュミンの類似体であるペンタガマブノン-1 (PGV-1) の治療の可能性を調査する.
- MYCN/ NCYM過剰発現のHCCにおけるPGV-1の増殖抑制および細胞死誘発の有効性を評価する.
- PGV-1の抗がん効果の基礎にある分子メカニズムを解明する.
主な方法:
- MYCN陽性JHH-7細胞を含むHCC細胞系を用いたインビトロ研究
- 細胞増殖,ミトス停止,酸化ストレス,衰老の評価
- キータンパク質のリン酸化 (オーロラA,サイクリンB1,PLK1) とMYCN/NCYM発現の分析
- 腫瘍の成長抑制を評価するためのイン・ビヴォの異種移植マウスモデル.
主要な成果:
- カーキュミンとソラフェニブと比較して,PGV-1はHCC細胞増殖を抑制することが示されました.
- PGV-1はHCC細胞のミトス停止,酸化ストレス,老化を誘発した.
- PGV-1による治療は,MYCN陽性細胞におけるオーロラA,サイクリンB1,PLK1のリン酸化を増加させた.
- PGV-1はMYCN/NCYMの転写を抑制し,MYCNタンパク質を不安定化した.
- PGV-1 治療を受けた異種移植モデルでは,腫瘍の形成と成長の有意な減少が観察されました.
結論:
- PGV-1はHCCにおいて強力な抗増殖および腫瘍阻害効果を発揮する.
- この化合物は,細胞サイクル調節とタンパク質の不安定化を含む複数のメカニズムを通じて,MYCN/ NCYMの過剰発現を標的としています.
- PGV-1は,MYCN過剰発現のHCCに対する有望な標的治療候補であり,さらなる臨床研究が必要である.
関連する概念動画
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Negative Regulator Molecules
35.9K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.9K


